3rd Mar 2020 14:18
Press release
Publication of Form 20-F
London: Tuesday, March 3, 2020: Hutchison China MediTech Limited ("Chi-Med") (NasdaqAIM: HCM) today published the Form 20-F for the financial year ended December 31, 2019. This is available for viewing at http://www.rns-pdf.londonstockexchange.com/rns/8821E_1-2020-3-3.pdf and also on the website of the Company at www.chi-med.com.
About Chi-Med
Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.
CONTACTS
Investor Enquiries |
| |
Mark Lee, Senior Vice President | +852 2121 8200 | |
Annie Cheng, Vice President | +1 (973) 567 3786 | |
David Dible, Citigate Dewe Rogerson | +44 7967 566 919 (Mobile) [email protected] | |
Xuan Yang, Solebury Trout | +1 (415) 971 9412 (Mobile)[email protected] | |
|
| |
Media Enquiries |
| |
UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson | +44 7973 611 888 (Mobile)[email protected] | |
Americas - Brad Miles, Solebury Trout | +1 (917) 570 7340 (Mobile)[email protected] | |
Asia | - Joseph Chi Lo, Brunswick | +852 9850 5033 (Mobile)[email protected] |
| - Zhou Yi, Brunswick | +852 9783 6894 (Mobile)y[email protected] |
|
| |
Nominated Advisor |
| |
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited | +44 (20) 7886 2500 | |
Related Shares:
Hutchmed